Key result
Glucose-lowering therapy cuts major cardiovascular events ~10% vs placebo in older T2D patients, driven by GLP-1RA.
Why the study?
Older adults with T2DM and CVD are under-represented in cardiovascular outcome trials, leaving uncertainty about whether the cardiorenal benefits of contemporary glucose-lowering drugs persist, attenuate, or amplify with advancing age.
Do SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors reduce major adverse cardiovascular events in geriatric patients (≥65 and ≥75 years) with type 2 diabetes mellitus and cardiovascular disease?
Meta-Analysis (n=105,752)
Yes
Do SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors reduce major adverse cardiovascular events in geriatric patients (≥65 and ≥75 years) with type 2 diabetes mellitus and cardiovascular disease?
Geriatric patients (≥65 and ≥75 years) with type 2 diabetes and cardiovascular disease experience higher baseline cardiovascular risk than younger patients but derive preserved relative and greater absolute reductions in MACE, heart failure hospitalisation, and cardiovascular death from GLP-1 receptor agonists and SGLT2 inhibitors.
Answers are grounded in this paper and cite their sources.
Supports GLP-1RA use to reduce MACE in patients ≥65 years with T2DM and CVD; extends CVOT evidence to geriatric subgroups with preserved relative benefit.
Introduction: Older adults carry the largest absolute burden of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD), yet they are under-represented in cardiovascular outcome trials (CVOTs), and clinicians remain uncertain whether the cardiorenal benefits of contemporary glucose-lowering drugs persist, attenuate or amplify with advancing age. We aimed to quantify the excess risk of adverse clinical outcomes conferred by older age in patients with T2DM and CVD, and to synthesise the efficacy and safety of sodium–glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) specifically in geriatric patients. Methods: This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement. PubMed, Europe PMC, Semantic Scholar and ClinicalTrials.gov were searched for reports published between 16 November 2011 and 16 November 2026, supplemented by citation searching. Randomised controlled trials (RCTs) reporting age-stratified outcomes (≥65 or ≥75 years), comparative cohort studies and case series in older adults were eligible; systematic reviews were reserved for the discussion. Risk of bias was assessed with RoB 2 and ROBINS-I. Hazard ratios (HRs) were pooled with DerSimonian–Laird random-effects models, with Hartung–Knapp–Sidik–Jonkman (HKSJ) adjustment and 95% prediction intervals. Effect modification by age was quantified as within-trial ratios of HRs, and prognosis as control-arm risk ratios (RRs) for older versus younger participants. Certainty of evidence was graded with GRADE. Results: Nineteen studies were included: 10 age-stratified analyses representing 11 CVOTs (105,752 randomised participants; 43,692 aged ≥65 years and 10,172 aged ≥75 years) and 9 cohort studies (approximately 1.43 million analysed patient records aged ≥65 years). In control arms, older age was associated with higher risks of major adverse cardiovascular events (MACE; RR 1.58, 95% CI 1.38–1.81), all-cause death (RR 2.03, 1.61–2.57), hospitalisation for heart failure (HHF; RR 1.88, 1.56–2.26) and severe hypoglycaemia (RR 1.54, 1.25–1.90). Versus placebo, glucose-lowering therapy reduced MACE in patients aged ≥65 years (HR 0.90, 0.82–0.98; k = 9; I² = 50%), driven by GLP-1RA (HR 0.85, 0.76–0.94) with directionally favourable SGLT2i (HR 0.90, 0.74–1.08) and neutral DPP-4i (HR 1.02, 0.89–1.16). In patients aged ≥75 years, MACE (HR 0.82, 0.70–0.97) and cardiovascular death (HR 0.67, 0.51–0.87) were reduced. HHF was reduced (HR 0.85, 0.74–0.97; I² = 1%), whereas all-cause death (HR 0.94, 0.79–1.11) and severe hypoglycaemia (HR 0.84, 0.65–1.09) were not significantly changed. The ratio of HRs for MACE in older versus younger participants was 0.98 (0.85–1.13), indicating no attenuation of relative benefit with age. In cohorts, SGLT2i versus DPP-4i was associated with lower all-cause mortality (HR 0.68, 0.58–0.81) and MACE (HR 0.72, 0.61–0.84) but heterogeneous HHF effects (HR 0.77, 0.56–1.06; I² = 98%) and more genital infections (HR 2.04, 1.43–2.91); GLP-1RA versus DPP-4i was associated with lower MACE (HR 0.76, 0.67–0.85), and SGLT2i versus GLP-1RA with lower HHF (HR 0.73, 0.67–0.81). Because baseline risk is high, approximately 32 MACE (NNT 31) and 38 cardiovascular deaths (NNT 27) could be prevented per 1000 patients aged ≥75 years treated over 2–5 years. Discussion: Advancing age amplifies the absolute cardiovascular, heart-failure and hypoglycaemic risk of patients with T2DM and CVD, whereas the relative benefit of cardioprotective glucose-lowering drugs is preserved. The combination of an age-invariant relative risk reduction with a steep, age-dependent baseline risk translates into greater absolute benefit in the oldest patients. Real-world data extend these signals to octogenarians but are limited by residual confounding and heterogeneity. Conclusion: Geriatric patients with T2DM and CVD have markedly worse clinical outcomes than younger patients but derive at least equivalent relative, and larger absolute, benefit from GLP-1RA and SGLT2i. Chronological age alone should not preclude cardioprotective therapy; treatment should be individualised through comprehensive geriatric assessment, and dedicated trials in frail and very old adults are needed.
No takes yet. Share an insight, caveat, or question.
Mujidiatama et al. (2026) conducted a meta-analysis in Type 2 diabetes mellitus and cardiovascular disease (n=105,752). Glucose-lowering therapy (SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors) vs. Placebo added to standard care (RCTs) or active comparator (cohorts) was evaluated on 3-point major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in patients aged ≥65 years (HR 0.90, 95% CI 0.82-0.98). Glucose-lowering therapy reduced major adverse cardiovascular events compared with placebo in patients aged ≥65 years with T2DM and CVD, driven by GLP-1RA.
Synapse has enriched 10 related papers. Consider them for comparative context: